FDA approves Biogen’s Alzheimer drug; company’s shares surge
TheAlzheimer’s drug, named Aduhelm, is expected to earn the company billions ofdollars as revenue. The stock of the company was trading at 60 per cent at onepoint on Monday
By
Published - Jun 07, 2021, 10:11 PM ET
Last Updated - Feb 09, 2024, 12:45 PM EST
By Shubhangi Mathur 4:38 pm ET
Food and DrugAdministration(FDA) approved Alzheimer’s disease drug aducanumab by Biogen—the firstdrug approved by US regulators which slows cognitive decline in peoplesuffering with the disease.
TheAlzheimer’s drug, named Aduhelm, is expected to earn the company billions ofdollars as revenue. The stock of the company was trading at 60 per cent at onepoint on Monday.
“We are well-aware of the attention surrounding thisapproval,” Dr. Patrizia Cavazzoni, director of the FDA’s Center for DrugEvaluation and Research, said in a press release. “We understand that Aduhelmhas garnered the attention of the press, the Alzheimer’s patient community, ourelected officials, and other interested stakeholders.”
